KRAS inhibitors

Harvard study finds way to extend KRAS drug response in pancreatic cancer

Researchers at Harvard Medical School have identified a way to transform the short-lived benefits of KRAS inhibitors in pancreatic cancer into lasting remissions by enlisting CD4 T-cell immunity through an IL-21 mimetic strategy. The findings, published Wednesday in Cell, address…